The enteral and parenteral medical nutrition market size is projected to reach US$ 32,408.02 million by 2031 from US$ 18,377.13 million in 2023. The market is expected to register a CAGR of 7.3% during 2023–2031. Specific formulations and plant-based nutritional products are likely to serve as key trends in the market.
The growth of the market is mainly fueled by the growing investments from international players, improving government support in countries such as China, supportive initiatives and nutrition research, and advancing healthcare infrastructure. The macro and micronutrient formulations of enteral and parenteral nutrition and their applications vary based on different diseases, such as cancer and gastrointestinal diseases. Energy-dense formulae (>1 kcal/ml) are prescribed to increase calorie delivery in patients with gastrointestinal dysfunction. A rise in the number of people turning to plant-based food causes the demand for plant-based nutrition products worldwide. The Innova Consumer Survey 2020 revealed that diet variety, health, sustainability, and taste are among the most important reasons why people consider plant-based alternatives. Companies (Kate Farms, Functional Formularies, and Real Food Blends) in the market anticipate that a rising focus on healthy foods will change into a preference for healthier nutrition products. As a result, companies have developed more natural and plant-based enteral products. Moreover, the rising geriatric population, growing incidence of chronic diseases and neurological disorders, and product innovations by the market players are anticipated to support the market growth.
According to the Centers for Disease Control and Prevention (CDC) data, preterm birth in the US accounted for 10% of all births in 2020 and reached 10.5% in 2021, recording a yearly rise of 4%. According to the July 2022 data of the United Nations International Children's Emergency Fund, the prevalence of undernourishment increased 9.3% in 2020 from 8.0% in 2019; it again jumped to 9.8% in 2021. Similarly, as per a study titled “A multi-center survey on hospital malnutrition,” published in 2021, about 33% of patients in US hospitals were either malnourished or at nutritional risk, and approximately 11–45% of hospital patients and home care settings patients in England suffered from malnutrition. Thus, the enormous burden of malnutrition in children and adults, along with a high number of preterm births, fuels the demand for enteral and parenteral medical nutrition products, which in turn stimulates the growth of the market.
You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities
Enteral and Parenteral Medical Nutrition Market: Strategic Insights
Bowel obstruction, Crohn’s disease, ulcerative colitis, short bowel syndrome (SBS), and certain cancers are some examples of gastrointestinal diseases. As per the “Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study,” published in January 2021, functional gastrointestinal disorders have affected more than 40% of people across the world. Research conducted by Crohn’s & Colitis UK confirms that ~1 in every 123 people in the country had either Crohn’s disease or ulcerative colitis in 2022, accounting for ~0.5 million people living with IBD in the UK. Moreover, SBS occurs in ~3 per 1 million people yearly. Patients with gastrointestinal diseases are at an increased risk of nutritional degradation. They may also experience nutritional deterioration due to therapeutic dietary limitation and loss of appetite caused by anorexia or altered nutritional requirements, which can be due to the disease itself. Hence, medical nutrition is recommended for gastrointestinal disease patients as these patients cannot ingest food. The enteral and parenteral routes are ideal to provide them with essential nutrients. Therefore, the rising cases of gastrointestinal diseases drive the growth of the enteral and parenteral medical nutrition market.
Companies operating in the enteral and parenteral medical nutrition market continuously focus on strategic developments, which help them advance their sales, enlarge their geographic reach, and improve their capacities to cater to a greater than existing customer base. Some of the noteworthy developments in the market are mentioned below:
Therefore, the development of advanced products targeting numerous health issues and strategic moves allow companies in the market to create new or better products and new businesses to remain competitive in the market. Such strategic growth initiatives provide significant growth opportunities in the market.
Key segments that contributed to the derivation of the enteral and parenteral medical nutrition market analysis are indication, nutrition type, form, product type, route of administration, age group, and distribution channel.
The geographic scope of the enteral and parenteral medical nutrition market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
North America has dominated the enteral and parenteral medical nutrition market. The growth of the market in this region is attributed to the rising prevalence of chronic diseases, growing strategic developments by market players, and increasing preference for enteral and parenteral nutrition, as well as an upsurge in knowledge among individuals about the benefits of medical nutrition. According to an article titled “Trends in Parenteral Nutrition,” on average, ~34,000 patients receive parenteral nutrition annually in the US. Enteral tube feeding can be prescribed for treating more than 350 disease conditions in children. In addition, the US government is taking several initiatives to boost the enteral and parenteral medical nutrition market. For instance, the Feeding Tube Awareness Foundation is creating awareness about adopting feeding tubes and the benefits associated with them. The Canadian Digestive Health Foundation states millions of Canadians live with digestive disease. ~20 million Canadians, i.e., two of every three people, suffer from digestive disorders yearly.
Furthermore, the presence of major market players is likely to have a positive effect on the growth of the enteral and parenteral medical nutrition market in the coming years. In February 2021, Amsino Medical Group received the FDA 510(k) clearance for its Puggle enteral feeding pump and feeding set for pediatric and adult patients. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.
The regional trends and factors influencing the Enteral and Parenteral Medical Nutrition Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Enteral and Parenteral Medical Nutrition Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 18,377.13 Million |
| Market Size by 2031 | US$ 32,408.02 Million |
| Global CAGR (2023 - 2031) | 7.3% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Indication
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Enteral and Parenteral Medical Nutrition Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Enteral and Parenteral Medical Nutrition Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The enteral and parenteral medical nutrition market is evaluated by gathering qualitative and quantitative data post post-post-primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the enteral and parenteral medical nutrition market are listed below:
The “Enteral and Parenteral Medical Nutrition Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:
North America region dominated the enteral and parenteral medical nutrition market in 2023.
The increase in the prevalence of gastrointestinal diseases and growing cases of malnutrition and premature births are the most influential factors responsible for market growth.
Abbott Laboratories, Nestle SA, Nutricia International BV, Medtrition Inc, Fresenius Kabi AG, B. Braun SE, Smartfish AS, Nutrisens SAS, AYMES International Ltd, Medifood International SA, Easy Line Ltd, Charing Cross Scientific AS, Baxter International Inc, and Medica Nutrition Inc. are the market players in the enteral and parenteral medical nutrition market.
The estimated value of the enteral and parenteral medical nutrition market accounted for US$ 32,408.02 million in 2031.
The global enteral and parenteral medical nutrition market is estimated to register a CAGR of 7.3% during the forecast period 2023–2031.